Results 1 to 10 of about 718 (128)

Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections [PDF]

Journal of Fungi (Basel, Switzerland), 2020
Fosmanogepix is a first-in-class antifungal currently in Phase 2 clinical trials for the treatment of invasive fungal infections caused by Candida, Aspergillus and rare molds. Fosmanogepix is the N-phosphonooxymethylene prodrug of manogepix, an inhibitor
Karen J Shaw, Ashraf S Ibrahim
exaly   +4 more sources

Successful treatment of a resistant invasive disseminated Fusarium infection in an immunocompetent patient [PDF]

Medical Mycology Case Reports
Fusariosis is a severe fungal infection associated with high mortality rates and an increasing incidence. However, its treatment remains challenging due to the frequent resistance of Fusarium species to conventional antifungal therapies.
Frantzeska Frantzeskaki, Nikolas Stratopoulos, Sandra Elise van der Griend, Ioannis Renieris, Kostantinos Thomas, Iraklis Tsagkaris   +5 more
doaj   +3 more sources

New Perspectives on Antimicrobial Agents: Fosmanogepix [PDF]

Antimicrobial Agents and Chemotherapy
Invasive fungal infections (IFIs) are associated with high mortality rates and pose important therapeutic challenges because of the limited number of antifungal drug classes, their toxicity, and the emergence of resistance.
Frederic Lamoth
doaj   +2 more sources

The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis [PDF]

Infection and Drug Resistance
Anna Zubovskaia, Jose A Vazquez Division of Infectious Diseases, Department of Medicine, Wellstar MCG/Augusta University, Augusta, GA, USACorrespondence: Jose A Vazquez, Division of Infectious Diseases, Department of Medicine, Wellstar MCG/Augusta ...
Zubovskaia A, Vazquez JA
doaj   +2 more sources

Fusariosis in Mexico: cases and gaps to be addressed [PDF]

Frontiers in Cellular and Infection Microbiology
This mini-review synthesizes four decades of Mexican fusariosis literature, organizing cases into four clinical categories: ocular, superficial/cutaneous, invasive/disseminated, and central nervous system (CNS) disease.
Ricardo Rodriguez-Vargas, Blanca Esthela López-Soliz, María Alejandra Cuen-Vázquez, Domingo Martínez-Soto   +3 more
doaj   +2 more sources

Central Nervous System Aspergillosis: Advances in Diagnosis, Therapeutics, and Multidisciplinary Management (2026 Update). [PDF]

Mycoses
ABSTRACT Background Central nervous system (CNS) aspergillosis is a life‐threatening infection with mortality rates exceeding 50%, especially in immunocompromised patients. Significant challenges persist due to limited antifungal drug penetration into the CNS, emerging resistance, and diagnostic delays, despite advancements in therapy and diagnostics ...
Mansour MA, Wahid M, El Molla MAS, Helmy MH, Adel TM, Mostafa HN.   +5 more
europepmc   +2 more sources

Candida auris: a review of global epidemiology, multidrug resistance, and infection control in healthcare-associated outbreaks [PDF]

Frontiers in Cellular and Infection Microbiology
Candida auris, designated a critical-priority fungal pathogen by the World Health Organization, poses a growing threat to healthcare systems worldwide. Analysis of 80 peer-reviewed studies reveals five principal findings: (1) C.
Xuewei Du, Li Li
doaj   +2 more sources

The Silent Pandemic: Antifungal Resistance and the Future of Invasive Fungal Disease Management [PDF]

Microorganisms
Invasive fungal diseases (IFDs) represent an escalating global health threat, compounded by the rapid emergence of antifungal resistance (AFR). This review synthesizes the contemporary landscape of AFR from clinical and microbiological perspectives ...
Ruchika Bagga, Kumudhavalli Kavanoor Sridhar   +1 more
doaj   +2 more sources

Manogepix demonstrates potent in vitro activity against Aspergillus, Coccidioides, Scopulariopsis/Microascus, Rasamsonia, and Purpureocillium species, including strains with in vitro resistance to other antifungals [PDF]

Antimicrobial Agents and Chemotherapy
Manogepix, the active moiety of the prodrug fosmanogepix, is a novel investigational agent in clinical trials that inhibits Gwt1, depleting glycosylphosphatidylinositol (GPI)-anchored mannoproteins critical for fungal cell wall integrity.
Nathan P. Wiederhold, Hoja P. Patterson, Carmita Sanders, Connie Canete-Gibas   +3 more
doaj   +2 more sources

Innovative antifungal strategies to combat drug-resistant Candida auris: recent advances and clinical implications [PDF]

Frontiers in Cellular and Infection Microbiology
Candida auris is an invasive fungal pathogen recognized globally as a significant health threat due to its marked resistance to multiple classes of antifungal agents, including azoles, echinocandins, and polyenes.
Wei Du, Qihui Wang, Min Zhao
doaj   +2 more sources